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Most therapeutic agents are designed to target a molecule or pathway without
consideration of the mechanisms involved in the physiological turnover or removal
of that target. In light of this and in particular for Alzheimer’s disease, a number of
therapeutic interventions are presently being developed/investigated which target the
amyloid-β peptide (Aβ). However, the literature has not adequately considered which Aβ
physiological clearance pathways are necessary and sufficient for the effective action
of these therapeutics. In this review, we evaluate the therapeutic strategies targeting
Aβ presently in clinical development, discuss the possible interaction of these treatments
with pathways that under normal physiological conditions are responsible for the turnover
of Aβ and highlight possible caveats. We consider immunization strategies primarily
reliant on a peripheral sink mechanism of action, small molecules that are reliant on
entry into the CNS and thus degradation pathways within the brain, as well as lifestyle
interventions that affect vascular, parenchymal and peripheral degradation pathways.
We propose that effective development of Alzheimer’s disease therapeutic strategies
targeting Aβ peptide will require consideration of the age- and disease-specific changes
to endogenous Aβ clearance mechanisms in order to elicit maximal efficacy.
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Introduction
Alzheimer’s disease (AD) is characterized in part by the accumulation of the amyloid-
beta peptide (Aβ) within the brain parenchyma leading to cellular injury and ultimately
death, as well as along blood vessels resulting in vascular dysfunction (Querfurth and
LaFerla, 2010). It is suggested that the imbalance between Aβ production and clearance
in aging drives Alzheimer’s disease progression in late onset Alzheimer’s disease (Hardy
and Selkoe, 2002). In light of this, many clinical trials have been initiated over the last
20 years that have targeted removal or inhibition of Aβ production with very limited
to no success.1 The failure of these trials has been attributed to targeting Aβ too late
1www.clinicaltrials.gov
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in the disease process, after the now recognized prodromal
phase of Aβ accumulation in the absence of clinical symptoms
(Sperling et al., 2011). Although these treatment strategies show
high success rates in rodent models with amyloid precursor
protein (APP) overexpression, a major confound is the lack of
physiological deficits from aging and long term amyloid burden
in these models, which are present in AD patients. Subsequently,
endogenous Aβ degradation is diminished more prominently in
AD than in disease models, a fact which is often overlooked in the
development of treatments. This is a major contributing factor
to the lack of clinical efficacy of Aβ specific therapies (Tanzi
et al., 2004). We present three classes of AD treatments, and
discuss how they rely on, and interact with, three physiological
pathways of Aβ clearance. Firstly, we examine Aβ immunization
strategies, and their dependence on the peripheral sink. Then
we discuss the effectiveness of small molecule therapies targeting
APP cleavage in the context of reduced Aβ degradation in
the brain parenchyma. Finally, we present an array of lifestyle
interventions in the clinic for AD, and discuss how these preserve
vascular health, and how this may ultimately enhance interstitial
fluid (ISF) and soluble Aβ drainage mechanisms. We survey
therapeutic strategies that are presently in clinical development
and describe the Aβ degradation pathways that are necessary
for drug efficacy while highlighting potential disease-specific
confounds that may contribute to previously failed trials.
Immunization Strategies
Currently, there are both passive and active immunization
strategies being developed for Alzheimer’s disease. These
antibodies target various components of the AD pathology, such
as Aβ and tau, but we will focus on those targeting Aβ (Table 1).
The most prominent area of immunization research has
largely been focused on the development of antibodies against
Aβ. One passive immunization antibody currently undergoing
clinical trials is solanezumab [LY2064230]. It is the humanized
IgG1 analog of the murine m266.2 antibody, an anti-Aβ
monoclonal antibody (Samadi and Sultzer, 2011). In vitro studies
have shown solanezumab to have a strong affinity (Kd of
10−12) towards the middle region of Aβ13-28 and thus acts
primarily via a peripheral sink mechanism, although other
physiological buffers and endogenous Aβ binding proteins may
occur (DeMattos et al., 2001). The ‘‘peripheral sink’’ hypothesis
is based on the premise that antibodies minimally transverse the
blood-brain barrier (BBB) and thus clearance of Aβ from the
brain relies on antibodies binding to Aβ within the bloodstream.
Antibodies directed towards Aβ shift the balance of Aβ from
the brain and the surrounding vasculature, leading to an efflux
of Aβ into the periphery (DeMattos et al., 2001). However, in
AD, this ‘‘peripheral sink’’ may be compromised, as Aβ efflux
mechanisms may be less efficient or countered by influx of
Aβ transcytosis into the brain (Kurz and Perneczky, 2011).
Through rodent studies, it was shown that m266 treatment
rapidly increased plasma Aβ40/42, which directly correlated
with the amount of brain Aβ burden pre-treatment. These data
support the idea that m266 acted as a ‘‘peripheral sink’’ to directly
facilitate the efflux of Aβ from the brain (DeMattos et al., 2002).
Another advantage of solanezumab is the selective binding to
soluble Aβ, which greatly decreased the incidence of vasogenic
edema and microhaemorrhages that were associated with earlier
antibodies (Racke et al., 2005), called Amyloid Associated
Imaging Abnormalities in human trials (Sperling et al., 2011).
Phase 2 trials conducted in 52 mild-to-moderate AD patients
in a double blind, placebo-controlled manner demonstrated a
dose-dependent increase in plasma Aβ40 and Aβ42 as well as an
increase in unbound Aβ42 in the CSF. These results suggested
that solanezumab bound soluble Aβ, which thereby disrupted the
equilibrium between soluble and insoluble Aβ within the CNS,
resulting in reduction in the deposited Aβ burden (Farlow et al.,
2012). Two Phase 3 trials, EXPEDITION-1 and -2 conducted
in patients with mild-to-moderate AD did not show statistically
significant improvement in cognition or activities of daily living
as measured by the Alzheimer’s Disease Assessment Scales,
(ADASCog 11 and 12) or the Alzheimer’s Disease Centers
Scale for Activities of Daily Living (ADCS-ADL); however, there
were significant differences in secondary outcome measures
(Doody et al., 2014). Currently, there is a third Phase 3 trial in
2,100 mild AD patients who have elevated levels of Aβ plaques
(EXPEDITION-3, ClinicalTrials.gov identifier: NCT01900665),
a Phase 2/3 trial to test solanezumab in carriers of the APP,
presenilin-1 and presenilin-2 Alzheimer’s genemutations (DIAN
Study, ClinicalTrials.gov identifier: NCT01760005), and a Phase
2 study in seniors deemed to be at high risk for AD who
have amyloid positive PET scans (A4 Study, ClinicalTrials.gov
identifier: NCT02008357).
Early studies, using passive immunization in AD patients,
were often associated with microhemorrhages and vasogenic
edema (Racke et al., 2005). In an attempt to avoid these
side-effects, a humanized anti-Aβ monoclonal antibody with
an IgG4 backbone called crenezumab (MABT5102A) was
created (Adolfsson et al., 2012). Crenezumab is similar to
solanezumab in that both target the midsection of Aβ;
however, the IgG4 isotype reduces the risk of Fcγ receptor-
mediated overactivation of microglial cells potentially leading
to deleterious proinflammatory responses, while maintaining
effective Aβ phagocytosis and clearance (Adolfsson et al., 2012).
Furthermore, crenezumab recognizes both soluble Aβ oligomers
and multiple Aβ aggregates that are present in AD brains
(Adolfsson et al., 2012). In vitro experiments have shown that
crenezumab both neutralized and protected neurons against
toxic Aβ oligomers (Adolfsson et al., 2012). Phase 1 trials
have shown to be extremely promising, as a dose-dependent
increase in total plasma Aβ levels was observed to serum
crenezumab concentrations demonstrating significant target
interactions (Adolfsson et al., 2012). As well, no trial participants
developed vasogenic edema, demonstrating the safety of high
dose treatment (Adolfsson et al., 2012). Currently, there are
several Phase 2 trials with crenezumab being tested as a method
of prevention for carriers of the PSEN1 E280A mutations,
(Alzheimer’s Prevention Initiative, ClinicalTrials.gov identifier:
NCT01998841), on brain amyloid burden in mild to moderate
AD (BLAZE Study, ClinicalTrials.gov identifier: NCT01397578)
and a long-term safety extension study (ClinicalTrials.gov
identifier: NCT01723826).
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TABLE 1 | Therapeutic interventions presently under investigation for Alzheimer’s disease.
Treatment name Company Therapy type Ongoing clinical trial
phase
Clearance mechanisms
Solanezumab (LY2062430) Eli Lilly and Co Passive immunotherapy Phase 2/3 ongoing,
Phase 3 ongoing
“Peripheral Sink Hypothesis” via
LRP1 and ApoE, or astrocytes,
endothelial cells, pericytes via
PgP efflux pump across BBB,
and subsequent phagocytosis by
perivascular macrophages
Crenezumab (MABT51021A,RG7412) Genentech Passive immunotherapy Phase 2 ongoing
CAD106 Novartis
pharmaceuticals corporation
Active immunotherapy None FcRn-mediated IgG-assisted
Aβ efflux across BBB with
subsequent phagocytosis by
perivascular macrophages + a
non-Fc-mediated disruption of
plaque structure
ACI-24 (Pal1-15 acetate salt) AC immune SA Active immunotherapy Phase 1/2 ongoing
MK-8931 (MK-8931-09) Merck Small molecule Phase 2/3 ongoing,
Phase 3 ongoing
Suppression of Aβ production, so
endogenous ADEs can degrade
Aβ, such as: NEP, ECE-1, IDE,
ACE, MMP-2, MMP-3, MMP-9,
Plasmin
AZD3293 (LY3314914) AstraZeneca Small molecule Phase 2/3 ongoing
VTP-37948 Vitae pharmaceuticals Small molecule Phase I ongoing
E2609 Biogen Idec, Eisai Co., Ltd. Small molecule Phase I and Phase II
ongoing
TTP488 (PF-04494700) Pfizer, TransTech Pharma, Inc. Small molecule Phase III pending
Suppression of Aβ transcytosis
into the brain with endogenous
ADEs to degrade Aβ within brain,
such as: NEP, ECE-1, IDE, ACE,
MMP-2, MMP-3, MMP-9, Plasmin
There has also been some success in terms of active
Aβ immunotherapies for treatment of AD. Active Aβ
immunotherapies are potentially more cost-effective and long-
lasting compared to passive Aβ immunotherapies, which require
recurring antibody infusions. Studies have shown an increase
in cross-reactive, potentially protective Aβ autoantibodies as
a result of active immunotherapy treatment in vervets, which
are much lower in AD patients when compared to healthy,
age-matched individuals (Weksler et al., 2002; Britschgi et al.,
2009). However, active Aβ immunotherapies often require
the use of a strong adjuvant for antibody production that
may be detrimental to elderly patients who already exhibit an
above average proinflammatory cytokine levels (Michaud et al.,
2013b).
CAD106 is one such active immunization strategy that is
currently in clinical trials. CAD106 was designed with multiple
Aβ1-6 coupled to a virus-like Qβ particle, to avoid activation of
inflammatory T cells (Wiessner et al., 2011). In APP transgenic
mouse studies, CAD106 administration generated Aβ-specific
antibodies without activation of Aβ-specific T cells (Wiessner
et al., 2011). In prevention trials, CAD106 immunization
significantly reduced plaque formation in APP24 mice, however
in treatment trials of advanced plaque formation, efficacy
was reduced. CAD106 treatment had no effect on levels of
vascular Aβ and proinflammatory cytokines, and did not increase
microhemorrhages. CAD106 treatment in rhesus monkeys,
which share similar Aβ sequences to humans, showed a dose
dependent increase in antibody production and Phase 1 trials
in humans have found similar results (Wiessner et al., 2011;
Winblad et al., 2012). Phase 1 trials showed that CAD106 did not
have any adverse effects related to the treatment and a significant
portion of the patients treated (67% in cohort 1 and 82% in cohort
2) developed Aβ antibody response that met the responder
threshold (Winblad et al., 2012). Phase 2 trials were designed
to establish antibody responses and tolerability to various doses,
different regions of injection, and different doses of adjuvant.
Partial results from Phase 2 findings have reported that long-
term exposure to high amounts of CAD106 did not have any
additional safety findings (Graf et al., 2014; ClinicalTrials.gov
identifier: NCT01097096).
ACI-24 is another active immunization method under
developed (Nicolau et al., 2002). ACI-24 is an Aβ1-15 peptide
that is bound to liposomal surfaces through two palmitoylated
lysine residues, forming a tandem at each end of the peptide
(Muhs et al., 2007). The Aβ1-15 sequences were chosen as it
retained the B cell epitope of Aβ, but lacked the T cell activation
epitope (Monsonego et al., 2001, 2003). ACI-24 treatment
restored memory deficits in mice, and produced mainly isotopes
IgG, IgG2b, and IgG3, whereby the first two IgGs are related
to noninflammatory Th2 response and the latter is a T cell-
independent IgG subclass (Gavin et al., 1998; Muhs et al.,
2007). Double transgenic mice treated with ACI-24 showed
an improvement in memory function which correlated with
an increase in IgG antibodies (Sigurdsson et al., 2004; Muhs
et al., 2007). Furthermore, treatment resulted in significant
reductions in both insoluble Aβ40 and Aβ42, as well as soluble
Aβ42, with slight decreases in soluble Aβ40. This effect was
observed without additional microglial activation, astrogliosis,
or proinflammatory cytokine production (Muhs et al., 2007).
Currently, there is a Phase 1/2 trial to examine the safety,
tolerability, immunogenicity and efficacy of ACI-24 in mild-to-
moderate AD patients (EudraCT Number: 2008-006257-40).
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Efflux Pathways for Clearance of Aβ
Since only 0.1% of all peripherally administered or in vivo
generated antibodies cross the BBB, then the efflux of Aβ from
the brain and subsequent degradation pathways in the periphery
will be required for effective passive or active immunization
strategies targeting Aβ (Banks et al., 2002; Morgan, 2011).
The major efflux pathway for Aβ across the BBB is via the
low density lipoprotein receptor-related protein -1 (LRP-1;
Kanekiyo and Bu, 2014). LRP-1 is a large multi-functional
receptor that regulates endocytosis of multiple ligands directly
or indirectly through interaction with other ligands, such as
Apolipoprotein E (ApoE), α2-macroglobulin, or other receptor
associated proteins many of which have been implicated in AD
pathogenesis (Liu et al., 2013; Kanekiyo and Bu, 2014). LRP-
1 is abundantly expressed on neurons, glia and vascular cells
within the brain and thus, is ideally located as a mechanism for
Aβ clearance. For the present argument, LRP-1 is expressed on
the microvascular including capillaries, venules and arterioles
(Sagare et al., 2013). Furthermore, in AD patients and a mouse
model of cerebrovascular amyloid angiopathy (CAA), LRP-1
staining is greatly reduced on vessels and is co-localized to
amyloid plaques (Shibata et al., 2000; Deanne et al., 2004;
Donahue et al., 2006). LRP-1 expression is also reduced in an
age-dependent manner on microvasculature adding further to
the potential deficits in Aβ efflux from the brain (Johanson et al.,
2006). As mentioned, LRP-1 transports other ligands such as
ApoE, the major lipid/protein chaperone in the brain which
is known to bind directly to Aβ. There are 3 ApoE isoforms,
ApoEε4 representing a risk factor for AD and having the lowest
affinity for Aβ, ApoEε2 which represents a protective factor with
a high binding affinity, andApoEε3which has an affinity between
the two (Liu et al., 2013). Thus the differential affinity of the
ApoE isoforms for Aβ binding could have further deleterious
implications for the clearance of Aβ.
Studies on aging and AD have suggested that there is an
increased permeability of the BBB with age and AD progression,
as a result of oxidative stress and vascular changes, suggesting
that passive diffusion of Aβ across the BBB might also contribute
to Aβ efflux (Kalaria and Hedera, 1995; Marques et al., 2013).
Under these conditions, a role for perivascular macrophages,
pericyte or endothelial cell uptake, and degradation of Aβ after
diffusion may also contribute (Verbeek et al., 2000; Hawkes
and McLaurin, 2009). However, it has been proposed that
macrophage function decreases with aging and pericytes are
extremely sensitive to Aβ-induced toxicity, therefore the balance
between these processes must be considered (Sengillo et al.,
2013).
Lastly, the receptor for advanced glycation end-products
(RAGE) plays an important role in AD by contributing to
Aβ-induced neuronal dysfunction, microglial activation, and a
key role in Aβ transcytosis into the brain (Yan et al., 1996, 2012;
Deane et al., 2003; Origlia et al., 2008, 2010). In AD, Aβ can act as
a ligand for RAGE and subsequently stimulate the upregulation
of RAGE via a positive feed-back mechanism (Bierhaus et al.,
2005). With RAGE-induced influx of Aβ into the brain, RAGE
activity may negate the already compromised effects of Aβ efflux
pathways, resulting in no change to the overall brain Aβ levels
(Kurz and Perneczky, 2011). An oral inhibitor of RAGE, TPP488
(PF-04494700) has been shown to block these interactions.
In vitro studies showed that TPP488 inhibited soluble RAGE
binding to RAGE ligands, but more importantly in this context,
to Aβ42.2 Phase 2 trials in people with mild-to-moderate AD
showed that TPP488 was well tolerated in subjects that received
either a low 10 mg or a high 20 mg dose (Sabbagh et al., 2011;
ClinicalTrials.gov identifiers: NCT00566397, NCT00141661).
However, results were inconclusive with respect to plasma Aβ
levels and inflammatory markers, and there were no significant
differences in cognitive and functional measures (Sabbagh et al.,
2011). Recently, a Phase 3 trial of TPP488 in mild-to-moderate
AD patients starting in 2014 was announced. The combination
use of promoting Aβ clearance from the brain and blocking
re-entry may provide a more powerful treatment then either
strategy alone.
Small Molecule Inhibitors
Currently, small-molecule inhibitors are being developed to
inhibit various processes involved in Aβ plaque formation in
AD. One class of inhibitors that are presently under examination
by various studies are β-site APP Cleaving Enzyme (BACE)
inhibitors. As β-secretase plays a major role in the production
of Aβ peptides from APP, BACE inhibitors may reduce the
amount of Aβ that is produced, allowing for endogenous Aβ
clearance mechanisms to function more effectively. However, for
these small-molecule inhibitors to work, they must cross both
the BBB and enter the appropriate compartments within neurons
(Vassar et al., 1999; Gabathuler, 2010). Therefore, in addition
to target efficacy, BACE, these therapeutics must be developed
with the appropriate molecular weight and charge to overcome
these challenges (Pardridge, 2007). Specific BACE inhibitors are
discussed below and summarized in Table 1.
MK8931, a small molecule inhibitor of BACE 1 and BACE2,
has shown in Phase 1 trials that single doses of up to 500 mg were
well tolerated and met with reductions in CSF Aβ of up to 92% in
healthy individuals (Forman et al., 2012). Furthermore, MK8931
has shown to have a relatively long half-life, 20 h, which is ideal
for single daily dosing paradigms (Forman et al., 2012; Stone
et al., 2013). Currently, Phase 2/3 trials are examining the safety
and efficacy of MK-8931 at daily dosages of 12 and 40 mg, as well
as long-term treatment effects on ADAS-cog and ADCS-ADL
scores (EPOCH, ClinicalTrials.gov identifier: NCT01739348 and
APECS, NCT01953601).
AZD3293 (LY3314814) is an oral, brain permeable BACE
1 inhibitor, currently being developed by AstraZeneca and Eli
Lilly (Haeberlein et al., 2013). Mouse and guinea pig studies
have shown AZD3293 treatment resulted in a dose- and time-
dependent reduction in the amount of Aβ40/42 and soluble
β-APP in the brain, CSF and plasma (Haeberlein et al., 2013).
Results from quantitative analyses of soluble α-APP and β-
APP in healthy volunteers showed that AZD3293 treatment
resulted in a dose-dependent decrease in the amount of soluble
β-APP in the CSF, while soluble α-APP showed a similar
2http://www.ttpharma.com
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broadly dose-dependent increase (Höglund et al., 2014). Phase
1 trials of AZD 3293 have recently been completed. A Phase
2/3 trial is currently recruiting, and will examine the safety
and efficacy of the AZD 3293 over 2 years of treatment in
early AD (ClinicalTrials.gov identifier: NCT02245737). Clinical
Dementia Rating-Sum of Boxes (CDR-SOB) will be used as the
primary outcome measure, with ADAS-COG and ADCS-ADL
as secondary outcome measures, as well as other imaging and
clinical markers.
Another oral BACE inhibitor, VTP-37948, currently in
development by Vitae Pharmaceuticals, has shown good brain
penetrance and reduced CSF Aβ levels by up to 80% in preclinical
studies.3 At present, VTP-37948 is in Phase 1 trials with healthy
individuals to examine safety and tolerability, as well as the
pharmacokinetics and pharmacodynamics of the drug.
E2609 is a BACE1 inhibitor that is being developed by
Eisai Ltd. It has been shown to significantly inhibit Aβ40/42
production in both the CSF and plasma of cynomolgus
monkeys after oral dosing (Lucas et al., 2012). Partial results
from Phase 1 studies have shown E2609 was well tolerated
across all dosage treatments (up to 800 mg), and had a
prolonged effect in reducing plasma Aβ40/42 after a single
dosage in healthy individuals (Lai et al., 2012). Currently, trials
have been completed on patients with MCI and those with
evidence of Aβ pathology, and a dose-finding Phase 2 trial is
underway in patients with MCI and mild AD (ClinicalTrials.gov
identifier: NCT02322021). They also examined the safety and
pharmacology of the E2609 across Japanese and Caucasian
populations.
Further studies on BACE inhibitors must be conducted to
determine efficacy in target engagement as well as potential
off-target deleterious side-effects. Post-mortem analyses of AD
brains demonstrated increased BBB permeability in brain
regions, such as the hippocampus, which may aid BACE
inhibitors to reach their targets (Montagne et al., 2015). However,
>90% of AD patients exhibit CAA, amyloid deposition within
the vasculature of the central nervous system, resulting in
hypoperfusion as well as a physical barrier to influx of BACE
inhibitors (Revesz et al., 2002; Thal et al., 2008). BACE cleaves
many substrates, that play important roles in the nervous system,
and thus inhibition of BACE may also lead to deleterious effects
throughout the body. One example is neuregulin-1, a peptide
that is essential for heart and nervous system development as
well as the maintenance of muscle spindles (Britsch, 2007). Other
BACE1 substrates, seizure-protein 6, L1, CHL1 and contactin-2,
are important neural cell adhesion molecules that are crucial
for guidance and maintaining neural circuits (Kuhn et al., 2012;
Zhou et al., 2012). Furthermore, BACE1 KO mice demonstrate
problems in axon targeting, although this may represent a
developmental issue, re-programming of neural circuits and
adult neurogenesis (Rajapaksha et al., 2011). Therefore, the
consequences of total BACE inhibition on the critical function of
these other substrates need to be examined further, as the effects
of these BACE inhibitors on Aβ offers a promising therapeutic
route. An alternate and possibly less prone to deleterious
3http://www.alzforum.org
side-effects may be the development of modulators of BACE
activity rather than inhibitors.
Intraparenchymal Degradation Pathways
In order for small molecule therapies to be effective in AD,
they not only need to exhibit high CNS bioavailability but
also utilize endogenous parenchymal Aβ catabolism pathways.
In regards to the BACE 1 inhibitors described above, these
inhibitors will decrease new Aβ production and thus potentially
prevent further neuronal and vascular damage. However, at time
of treatment most AD patients will have a pre-existing Aβ load
within the CNS that may require catabolism for full recovery.
The endogenous parenchymal catabolic pathways for Aβ are
regulated by a number of degrading enzymes in the extracellular
space, secreted chaperones that monitor proteostasis, as well as
glial cell uptake and degradation by lysosomal, autophagic and
proteosomal pathways (Guénette, 2003; Tanzi et al., 2004; Lai and
McLaurin, 2012; Wyatt et al., 2012).
Enzymatic degradation of Aβ peptides is accomplished by
a number of enzymes including, but not limited to, neprilysin
(NEP), insulin degrading enzyme (IDE), angiotensin converting
enzyme (ACE) and various matrix metalloproteinases (MMPs).
NEP is the most extensively studied, and has been shown to
degrade both Aβ40 and Aβ42 in vitro and in vivo (Iwata et al.,
2000, 2001). Furthermore, recent studies in aged mice and AD
patients have shown decreased levels of NEP in the hippocampus
and temporal gyrus, regions with a high amyloid load in
AD (Yasojima et al., 2001; Iwata et al., 2002). However, the
degradation of Aβ is complicated and cannot be accomplished
by a single enzyme, as Kms and Aβ aggregation state will play
a role. IDE has also been shown to have Aβ degrading activity,
as IDE deficient mice have increased brain Aβ levels and over-
expression in an AD mouse model decreases Aβ levels (Farris
et al., 2003; Leissring et al., 2003). Furthermore, insulin competes
with Aβ for IDE degradation and thus in Diabetes Mellitus, Aβ
levels are increased within the CNS (Qiu and Folstein, 2006). The
role of MMPs, ACE, endothelin-converting enzyme and others
all contribute to Aβ catabolism however the precise role for each
enzyme is not fully elucidated.
A recent hypothesis suggests that a family of secreted
chaperones, which exist in the extracellular space, patrol the
brain for misfolded proteins and aid in clearance (Wyatt
et al., 2012). The chaperones relating to Aβ clearance that
have been identified are clusterin (also referred to as ApoJ),
α2-macroglobulin and ApoE. As mentioned above, all three
chaperones are co-receptors for LRP-1 and thus aid in Aβ
catabolism via uptake by neurons, glia or vascular cells.
In AD, astrocytes and microglia are the immune effectors of
the CNS and thus play a role in injury resolution via limiting
effects of toxic Aβ species (Guénette, 2003). Astrocytes become
activated and surround amyloid plaques in an attempt to limit
the damage to surrounding neuropil (Akiyama et al., 2000).
Examination of human AD brain demonstrated the presence
of N-truncated Aβ within astrocytes and more specifically Aβ
was detected in lysosomal granules of astrocytes, thus suggesting
phagocytosis and degradation (Funato et al., 1998; Thal et al.,
1999; Nagele et al., 2003). In support of the pathological findings,
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adult mouse astrocytes have been shown to degrade Aβ deposits
in brain sections, and phagocytose extracellular Aβ (Wyss-Coray
et al., 2003; Koistinaho et al., 2004; Mandrekar et al., 2009).
Although astrocyte uptake and degradation is less efficient then
resident microglial cells, this pathway may contribute to Aβ
clearance under treatment strategies.
Microglial cells are the resident phagocytes of the CNS
and play a significant role in Aβ clearance (reviewed in Lai
and McLaurin, 2012). Although microglial cells in vitro readily
phagocytose and degrade soluble and fibrillary Aβ, there is
some controversy regarding efficacy under the pathological
conditions present in AD brains (Lee and Landreth, 2010).
Similar to astrocytes, microglia surround amyloid plaques, and
electron microscopy studies have suggested the intracellular
presence of Aβ in endosomal compartments (Frackowiak et al.,
1992). Furthermore, Aβ can be detected within lysosomal
compartments of non-plaque associated microglial cells after
treatment with an anti-aggregant compound, 1-fluoro-scyllo-
inositol (Hawkes et al., 2012). Thus, although some literature
suggests that accumulation of Aβ and amyloid plaques may be
the result of immuno-incompetent microglia in AD, the presence
of small molecules therapies, such as immunotherapy, curcumin
and scyllo-inositol, that boost phagocytosis support a role for
microglia in therapeutic interventions (Wilcock et al., 2004;
McLaurin et al., 2006; Yanagisawa et al., 2010).
Lifestyle Interventions
In recent years, AD research has begun to focus on changes
that can be made in daily living and activity which potentially
decrease risk and delay symptomatic expression of AD. During
the International Conference on Nutrition and the Brain a
compilation of the presented data led to the identification
of 7 changes to be integrated into daily living, six involving
diet and the seventh recommending exercise (Barnard et al.,
2014). Exercise and diet alterations have been associated with
improvements in symptomatic and pathophysiological AD
outcomes in both animal models and humans (Luchsinger et al.,
2002; Stranahan et al., 2012; Hawkes et al., 2015; Lim et al., 2015;
Lin et al., 2015). Regular, controlled diet and exercise are likely
protective against AD pathogenicity through the maintenance
of cardiovascular and cerebrovascular health. As mentioned
above, the vasculature plays a crucial role in the clearance of
Aβ across the BBB because of receptors (i.e., LRP-1, RAGE)
expressed on the plasma membranes of capillary, arteriole, and
small venule cells (Deane et al., 2003; Sagare et al., 2013). It
has recently become apparent that regular and healthy pulsation
of blood vessels promote a convective bulk flow of the brain’s
parenchymal ISF, which acts to clear toxic solutes such as Aβ
(Carare et al., 2008; Weller et al., 2008; Iliff et al., 2012). Lifestyle
interventions, including exercise, diet and sleep, may have direct
beneficial effects onAβ clearance, as well as act indirectly through
enhancing vascular health.
Exercise
There are >20 ongoing and recently completed clinical trials
assessing the efficacy of different exercise interventions on AD
symptoms and pathology.4 Thoroughly detailing these trials is
beyond the scope of this review, however a few points will
be noted. Firstly, exercise has had beneficial effects on many
cognitive assessments (de Andrade et al., 2013; Winchester
et al., 2013; Okonkwo et al., 2014). Secondly, AD interventional
benefits are seen in amultitude of exercises ranging fromwalking
to high-intensity aerobic physical activity (Venturelli et al., 2011;
Nascimento et al., 2012; Vidoni et al., 2012; Hoffmann et al.,
2013; Suttanon et al., 2013; Winchester et al., 2013; Arcoverde
et al., 2014; Okonkwo et al., 2014). Finally, regular exercise over
years is correlated with significantly slowed Aβ deposition over
time, perhaps in part due to enhanced Aβ clearance (Okonkwo
et al., 2014).
The beneficial effects of aerobic exercise on brain health have
been well studied in recent years, with a focus on enhanced
neurogenesis, increased levels of neurotrophic factors such as
brain-derived neurotrophic factor (BDNF), and reduced risk
for AD (Voss et al., 2013). Lin et al. (2015) demonstrated that
exercise is associated with improved Aβ clearance mechanisms
by upregulation of LRP-1 protein levels whereas RAGE was
unchanged (Lin et al., 2015). Interestingly, one study in the
Tg2576 AD mouse model demonstrated reduced soluble Aβ, but
unchanged total Aβ, as a result of exercise (Nichol et al., 2008).
This further suggests that Aβ clearance mechanisms specifically
are upregulated with exercise. BDNF signaling in the brainstem
of mice has recently been shown to increase the excitability
of parasympathetic cholinergic neurons which, by way of the
vagal nerve, act to lower resting heart rate (Wan et al., 2014).
This provides molecular evidence for a mechanism by which
aerobic exercise can reinforce vascular health (Wan et al., 2014;
Mattson, 2015). Since the structurally and functionally impaired
cerebrovasculature in AD dampens blood vessel-dependent Aβ
clearance pathways, physical activities which can upregulate
BDNF signaling and provide enhanced amyloid removal to the
periphery, would be beneficial in slowing disease progression
(Dorr et al., 2012; Lai et al., 2015).
Diet
Healthy diet maintenance is important in the modulation of AD
symptoms and pathology, assisting endogenous mechanisms
including neurogenesis, antioxidant protection, and Aβ
clearance (Aliev et al., 2013; Maruszak et al., 2014). Type 2
Diabetes Mellitus (T2DM) is an acquired disease caused by
hyperglycaemia and potentially insulin resistance. The main
risk factors for the incidence and prevalence of T2DM are
obesity, primarily from high fat diets, and age (Barbagallo and
Dominguez, 2014; Centers for Disease Control and Prevention,
2014). Studies have shown that T2DM patients are at an
increased risk of developing dementia, and conversely, 80% of
AD patients have T2DM (Janson et al., 2004; Biessels et al., 2006).
In a recent study by Hawkes et al. (2015) mice that were subject
to a high fat diet during gestation and early life exhibited deficits
in perivascular clearance of Aβ, an effect which was exacerbated
when the high fat diet was lifelong. Also, vascular deposits of Aβ
in aged human cases of hyperlipidemia were significantly greater
4www.clinicaltrials.gov
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when compared to aged-matched people with normal lipid levels
post-mortem (Hawkes et al., 2015).
Dietary plans have been well researched in AD. The
main three are the Mediterranean, ketogenic, and caloric
restriction diets (Aliev et al., 2013; Maruszak et al., 2014).
The Mediterranean diet involves replacement of meat products,
especially red meat, with plant-based alternatives, and primarily
olive and fish oils for additional fats (Yannakoulia et al., 2015).
Clinical studies on the effect of this diet on cognition in MCI/AD
are inconsistent, with some showing benefits and others not
(Olsson et al., 2015; Yannakoulia et al., 2015). Contrary to
the Mediterranean diet, ketogenic and caloric restriction diets
involve a significant reduction in food intake (Maruszak et al.,
2014; Paoli et al., 2014). The ketogenic diet aims to create a
state of fasting within the body (Paoli et al., 2014). This reduces
metabolic induced stresses, including damage from reactive
oxidative species and pathogenic mitochondrial biogenesis (Paoli
et al., 2014). Ketogenic diets may also decrease the production
of advanced glycation end products, which accumulate on Aβ
plaques, potentially assisting in one of the aforementioned
clearance cascades by decreasing reuptake of Aβ by RAGE
(Deane et al., 2003; Srikanth et al., 2011; Paoli et al., 2014).
Caloric restriction on the other hand, is achieved by a moderate
decrease in overall intake of calories (Maruszak et al., 2014).
Caloric restriction has been associated with a reduced risk of
AD and memory improvements in the elderly, and has been a
beneficial intervention in mouse models of AD (Lee et al., 2000,
2002; Luchsinger et al., 2002; Gustafson et al., 2003; Wu et al.,
2008; Witte et al., 2009). This diet has also been demonstrated
to decrease Aβ pathology through enhancing non-amyloidogenic
APP cleavage by α-secretase and increasing clearance of Aβ
through upregulated IDE levels (Farris et al., 2004; Wang et al.,
2005; Tang and Chua, 2008). There are two current clinical trials
on the effectiveness of caloric restriction in MCI/AD.
Sleep
Sleep and circadian rhythm disturbances are common in aging
and AD patients (Floyd et al., 2000; Cipriani et al., 2014;
Zelinski et al., 2014). Circadian rhythms are controlled by the
suprachiasmatic nucleus (SCN) in the hypothalamus, which acts
like a biological clock in its management of many physiological
functions (Reppert and Weaver, 2001; Coogan et al., 2013;
Videnovic et al., 2014; Zelinski et al., 2014). Mouse models of
AD exhibit circadian rhythm alterations suggesting a link to Aβ
(Sterniczuk et al., 2010; Baño Otalora et al., 2012). Even self-
reported disruptions in sleep indicate a 33% increased risk of
dementia and a 51% increased risk of AD (Benedict et al., 2014).
Higher brain amyloid burden and lower CSF Aβ levels were
observed in sleep deprived and narcoleptic patients without AD
(Spira et al., 2013; Liguori et al., 2014). AD animal models in
which sleep is deprived show similar trends of increased amyloid
load, as well as increased memory dysfunction (Kang et al., 2009;
Rothman et al., 2013; Di Meco et al., 2014).
A study in cognitively normal middle-aged men measured
CSF biomarkers of AD by an intrathecal catheter (Ooms
et al., 2014; AWAKE study, ClinicalTrials.gov identifier:
NCT01194713). A 6% decrease in Aβ42 levels were observed
following an unrestricted sleep, however no change was observed
in participants who remained awake (Ooms et al., 2014). The
benefits of sleep on soluble Aβ levels in the brain may have
been underestimated due to measurement of only spinal CSF
(Ooms et al., 2014). There is also enhanced clearance by the
glymphatic system during sleep, leading to additional Aβ efflux
into the blood and cervical lymph nodes (Szentistványi et al.,
1984; Iliff et al., 2012; Xie et al., 2013). Using in vivo two-
photon microscopy in sleeping and in anesthetized mice, Xie
et al. (2013) measured a 60% increase in the brain parenchyma,
associated with an increase in the rate of exchange of CSF-ISF.
These results suggest that regular sleep may serve to aid in the
clearance of toxic solutes, such as Aβ, from the extracellular space
in the brain, and normalization of sleep patterns may serve as
beneficial lifestyle intervention in the treatment of AD (Xie et al.,
2013).
There are 7 active clinical trials for sleep interventions in AD,
two of which are directly concerned with sleep apnea. Sleep apnea
causes pauses or disruptions in breathing during sleep, and is
correlated with cognitive dysfunction in AD patients (Janssens
et al., 2000; National Heart, Lung, and Blood Institute, 2012).
It is potentially associated with AD through mechanisms such
as cellular oxidative stress, hypoxia, and sleep disturbances (Pan
and Kastin, 2014). The two current clinical trials for sleep apnea
and AD are assessing the effectiveness of a continuous positive
airway pressure (CPAP) device on measurements including
cognition, quality of daily living and CSF levels of Aβ42
(AZAP, ClinicalTrials.gov identifier: NCT01400542 and SNAP,
ClinicalTrials.gov identifier: NCT01962779). The use of CPAP
has effectively improved sleeping conditions in patients with
mild-to-moderate AD, an effect that was maintained for 3 weeks
(Cooke et al., 2009).
Sleep apnea leads to impaired vascular health, with increased
arterial stiffness and blood pressure, decreased cerebral blood
flow, and thickened carotid intima-media (Daulatzai, 2012;
Ciccone et al., 2014). The tunica intima and tunica media are
the innermost perivascular layers along cerebral arteries, and
the tunica media is the area within which the majority of ISF
flows on its way out of the brain during perivascular clearance
(Carare et al., 2008; Weller et al., 2008, 2010). Therefore if
sleep disturbances are thickening this area, the rate at which
bulk flow of ISF travels would theoretically be decreased.
This, in conjunction with the impaired arterial health in sleep
apnea, would potentially diminish the perivascular clearance
of Aβ, leading to increased CAA and amyloid in the brain
parenchyma (Daulatzai, 2012). Nighttime wakefulness also leads
to a decrease in glymphatic Aβ clearance because of the inability
for parenchymal expansion, which normally speeds the rate of
CSF-ISF exchange during sleep (Xie et al., 2013). Both glymphatic
and perivascular clearance mechanisms are further diminished
by the impaired vasculature present in sleep disorders due to
irregular blood vessel pulsations (Carare et al., 2008; Iliff et al.,
2013b).
Vascular Health
Hypertension, increased body mass index, abnormal glucose
regulation, hyperlipidemia, and hypercholesterolemia are all
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vascular related risk factors for AD and cognitive decline
(Kivipelto and Solomon, 2008; Reynolds et al., 2010; Tolppanen
et al., 2012; Liu et al., 2014; Deckers et al., 2015). AD
patients analyzed for the relationships between cardiovascular
risk factors and cognition showed lower scores on the
MMSE and ADAS-COG in hypertensive patients compared
to those with normal blood pressure, and lower scores on
the MMSE and Clinical Dementia Rating in patients with
hyperlipidemia compared to those without (Lobanova and
Qureshi, 2014). Such findings suggest vascular injury may
play a role in cognitive dysfunction in AD. Vasoactive
drugs therefore might have the potential to treat aspects of
AD, including deficits in cognition. Two current vasoactive
drugs in development for AD are nilvadipine and cilostazol
(Ikeda, 1999; Nimmrich and Eckert, 2013). Nilvadipine is a
dihydropyridine that blocks calcium channels and prevents
cognitive decline in patients with MCI (Hanyu et al., 2007;
Nimmrich and Eckert, 2013). Although intervention with
Nilvadipine leads to decreased hypertension, its main effect
on cognition is postulated to be through neuroprotection,
potentially by decreased calcium-mediated excitotoxicity of
neurons (Takakura et al., 1992; Hanyu et al., 2007; Nimmrich and
Eckert, 2013). A Phase 3 placebo-controlled trial of nilvadipine
in mild-moderate AD is underway (NILVAD, ClinicalTrials.gov
identifier: NCT02017340).
Cilostazol has multiple beneficial effects on the vasculature,
antiplatelet activity, and is an inhibitor of the cAMP and cGMP
regulator phosphodiesterase type 3 (PDE3; Ikeda, 1999; Saito
and Ihara, 2014). Studies of cilostazol in human dementia/AD
patients showed some benefit on slowing cognitive decline
and increasing cerebral perfusion (Sakurai et al., 2013; Ihara
et al., 2014). Patients with mild dementia, but not moderate to
severe dementia, maintained higher MMSE scores when treated
with cilostazol in conjunction with the acetylcholinesterase
inhibitor donepezil, compared to donepezil alone (Ihara et al.,
2014; CASID study, ClinicalTrials.gov identifier: NCT01409564).
Slower decline in ADAS-COG scoring was also seen in another
study, along with increased regional cerebral blood flow to the
right anterior cingulate lobe (Sakurai et al., 2013). Cilostazol is
theorized to slow AD progression by promoting perivascular
clearance of ISF, which contains soluble Aβ, in part due
to it vasodilation and regulation of blood vessel pulsations
(Carare et al., 2008; Han et al., 2013; Saito and Ihara, 2014).
Additionally, PDE3 expression is increased in arterial cells
with Aβ deposition, primarily in smooth muscle cells (Maki
et al., 2014). Smooth muscle cells are present within the
tunica media of the perivascular space along leptomeningeal
arteries, a pathway through which ISF, including soluble Aβ, is
cleared from the brain (Weller, 2005; Kwee and Kwee, 2007;
Carare et al., 2008; Weller et al., 2008). In a mouse model
of CAA, cilostazol protected against vascular and cognitive
deficits, and decreased Aβ deposits, potentially because of
enhanced perivascular clearance (Maki et al., 2014). This
suggests beneficial effects of cilostazol in AD on perivascular
clearance of ISF, and on a vascular protective signaling cascade
involving inhibition of PDE3 and increased cAMP and cGMP
activity.
Perivascular Clearance
There are two proposed mechanisms by which drainage of the
brain’s extracellular fluid, also referred to as ISF, occur (Carare
et al., 2008; Iliff et al., 2012). The first involves a bulk flow of
ISF and solutes within arterial perivascular spaces, across the
BBB, where they enter cervical lymph nodes (Szentistványi et al.,
1984; Carare et al., 2008). Perivascular spaces, or Virchow-Robin
spaces, are small areas around blood vessel walls, including the
smooth muscle cells which line arteries, that are in continuity
with the subarachnoid space from the point where blood
vessels penetrate into the brain parenchyma (Weller, 2005; Kwee
and Kwee, 2007; Weller et al., 2008). The pia mater sheaths
the perivascular space along leptomeningeal arteries until they
branch off into smaller arterioles and capillaries (Weller, 2005;
Kwee and Kwee, 2007; Carare et al., 2008). According to one
theory, flow of ISF occurs along the basement membranes of
capillaries and arterioles until it converges upon leptomeningeal
arteries, where the fluid continues to drain in the perivascular
tunica media, the space between the arterial smooth muscle cells,
and in the tunica adventitia, the basement membranes of the
smooth muscle cells (Carare et al., 2008; Weller et al., 2008,
2010). There is further convergence with leptomeningeal and
major cerebral arteries before the ISF drains completely out of
the brain into the cervical lymph nodes (Szentistványi et al.,
1984; Weller et al., 2010). This theory implies that flow of ISF
occurs retrogradely only along capillaries, arterioles, and arteries,
not along venules or veins (Figure 1; Carare et al., 2008; Arbel-
Ornath et al., 2013).
Evidence for perivascular clearance has been obtained by
experiments involving radio- or fluorescent labeled tracers.
Furthermore, multi-photon imaging and mathematical models
have provided strong support (Szentistványi et al., 1984; Schley
et al., 2006; Carare et al., 2008; Wang and Olbricht, 2011; Arbel-
Ornath et al., 2013). ISF drainage was theorized to be by a
convective bulk flow mechanism by assessing the clearance of
multiple radiolabeled compounds of differing molecular weights.
These compounds cleared at the same rate, confirming that ISF
did not drain by diffusion, in which case the smaller molecules
would have moved faster (Cserr et al., 1981; Abbott, 2004; Carare
et al., 2008). Using multi-photon imaging through a surgically
dissected cranial window in mice, Arbel-Ornath et al. (2013)
observed active perivascular clearance of ISF in vivo. Consistent
with previous conclusions, the fluorescent tracer flowed out of
the brain along capillaries and arteries but not veins (Arbel-
Ornath et al., 2013). Perivascular clearance is reliant on proper
vasculature flow, as it is non-existent after cardiac arrest and
is diminished with decreased perfusion (Carare et al., 2008;
Arbel-Ornath et al., 2013). Theoretical models propose that the
pulsating motion of blood flowing into the brain acts to push ISF
in the opposing direction, thereby explaining why the draining of
ISF requires functioning vasculature, and why fluid is not cleared
along veins (Schley et al., 2006; Carare et al., 2008; Wang and
Olbricht, 2011).
Although Aβ self-aggregates into fibers and forms plaques,
there is still a significant portion of soluble species of Aβ
that is released to the extracellular space (Selkoe, 2001). Since
convective bulk flow of ISF drains solutes, perivascular drainage
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FIGURE 1 | Perivascular and glymphatic drainage of brain interstitial
fluid (ISF). These mechanisms drain brain ISF and parenchymal solutes (e.g.,
Aβ) to the periphery. Perivascular clearance involves ISF efflux along capillaries,
arterioles, and arteries within the perivascular space. Glymphatics involve CSF
influx and CSF/ISF efflux within the perivascular space along arteries and veins,
respectively. Color Legend, red: arteries/arterioles/capillaries; blue:
veins/venules; light blue: perivascular space; pink dotted line: ISF efflux; yellow
dotted line: CSF influx; purple dotted line: CSF/ISF efflux.
represents one of the major Aβ clearance mechanisms and could
be impaired in AD (Carare et al., 2008). The APP/PS1 ADmouse
model showed a 60% increased retention of fluorescent tracer,
compared to wild type mice (Arbel-Ornath et al., 2013). The
presence of Aβ plaques on arteries cause increased tortuosity
and decreased calibre which in turn disrupts and lengthens
blood flow transit times (Dorr et al., 2012). This irregularity
in the vasculature is likely interrupting the pulsating motion
which drives perivascular clearance. Also, it was found that
fluorescent conjugated tracers and Aβ40 when injected are
present where plaques would form in AD (Hawkes et al., 2013,
2014). The hippocampus of non-transgenic mice showed an
aging-related decrease in perivascular clearance of injected Aβ40,
suggesting the importance of this clearance mechanism to AD
pathogenesis (Hawkes et al., 2013). Together, these conclusions
support a positive feedback loop for CAA and AD, where
impaired perivascular ISF drainage leads to Aβ deposition along
the arteries, which causes weakened vasculature functioning,
thereby allowing increased levels of Aβ to remain in the brain
parenchyma, more specifically in the hippocampus (Carare et al.,
2008; Hawkes et al., 2013).
Glymphatics
The glymphatic system is another ISF drainage system recently
proposed by Maiken Nedergaard’s group (Iliff et al., 2012; Iliff
and Nedergaard, 2013). Glymphatics involve the para-arterial,
unidirectional flow of CSF from the cisterna magna of the
subarachnoid space, along penetrating leptomeningeal arteries,
towards the pituitary and pineal recesses of the 3rd ventricle,
and into the brain within the perivascular (Virchow-Robin) space
(Iliff et al., 2012, 2013a). CSF enters the brain parenchyma and
mixes with ISF in a process reliant on aquaporin-4 (AQP4)
channels present on the perivascular endfeet of astrocytes. The
extracellular fluid composed of CSF and ISF is proposed to
exit the parenchyma by drainage out of the brain within the
venous perivascular space of large calibre veins only, where
it then flows into the cervical lymph nodes, or absorbs into
the blood across arachnoid villi on dural sinuses (Figure 1;
Szentistványi et al., 1984; Iliff et al., 2012). Similar to perivascular
clearance, glymphatic flow is driven by the pulsation of blood
vessels; however, the former is by bidirectional flow along the
vasculature, and the latter is unidirectional (Hadaczek et al.,
2006; Schley et al., 2006; Wang and Olbricht, 2011; Iliff et al.,
2013b).
The glymphatic system was observed in vivo in mice after
an intrathecal injected contrast agent was followed by magnetic
resonance imaging, and through a closed cranial window with
two-photon laser scanning microscopy (Iliff et al., 2012, 2013a).
These results were reproduced using clinically-relevant levels of
intrathecal injections in rats and mice (Yang et al., 2013). In
confirmation that arterial pulsations drive the unidirectional flow
of CSF into the parenchyma, unilateral ligation of the mouse
carotid artery decreased blood flow and pulsality as well as flow
of the injected tracers. Subsequently, treatment with dobutamine
to increase blood flow and pulsality, increased tracer movement
(Iliff et al., 2013b).
Similar to perivascular clearance, soluble Aβ is cleared from
the brain parenchyma by glymphatic drainage (Carare et al.,
2008; Iliff et al., 2012). Interestingly, the rates of CSF-ISF
exchange significantly decrease with age, suggesting an age-
related decline in the glymphatic clearance of toxic solutes, such
as Aβ (Kress et al., 2014). Unlike perivascular clearance, the
physics of the overall drainage system are affected by molecular
size, because larger tracers were slower to enter the parenchyma
following subarachnoid injection, suggesting a reliance on AQP4
channels for CSF-ISF exchange (Iliff et al., 2012). In healthy
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conditions, the expression of AQP4 is highly polarized to
astrocytic endfeet (Iliff and Nedergaard, 2013). However, with
neuroinflammation as well as with age, this expression profile
changes, with decreased AQP4 at the perivascular endfeet and
increased levels in the soma. This may explain the impairment
in glymphatic flow with age, suggesting another mechanism
by which Aβ clearance may be diminished in AD (Iliff and
Nedergaard, 2013; Kress et al., 2014). Additionally, both the
perivascular and the glymphatic clearance systems are impaired
following an ischaemic stroke in mice (Arbel-Ornath et al., 2013;
Gaberel et al., 2014). Because of a close clinical relationship with
stroke, this provides further evidence to why drainage of Aβmay
be impaired in AD (Viswanathan et al., 2009).
In addition, late-onset AD is thought to relate to impaired
cerebral clearance of Aβ (Mawuenyega et al., 2010). This is in
contrast to overproduction which leads to amyloid accumulation
from mutations affecting APP processing (e.g., mutations in
APP or presenilin complex), resulting in early-onset Autosomal
Dominant AD or trisomy 21, which predisposes to early-onset
dementia in Down’s syndrome. In this context, collagenosis of
the deep penetrating venular system could be predicted to affect
the glymphatic clearance of amyloid and other toxic proteins
along the perivascular venular pathways. Collagenosis causes wall
thickening and stenosis of the deep venular system and correlates
with confluent periventricular white matter hyperintensities
(pvWMH), which is seen in elderly controls and Alzheimer’s
patients on Magnetic Resonance images (Moody et al., 1995;
Black et al., 2009). PvWMH are associated with hypertension
and other vascular risk factors, older age and possible genetic
factors. Recent work from our group suggests the correlation of
pvWMH is strongest with significant stenosis of the medium to
large venules. We hypothesize that this leads to BBB leakage and
perivenous edema, which further disrupts clearance mechanisms
for amyloid and other toxins along the perivascular pathways
(Black et al., 2009; Gao et al., 2012). It is of note that pvWMH
are also associated with CAA and visible as microbleeds, which
would be consistent with disruption of the perivascular pathway,
thereby exacerbating deposition of periarteriole Aβ (Pettersen
et al., 2008).
CAA and AD associated arterial damage, as described
above, would decrease the functioning of both perivascular and
glymphatic drainage by impairing arterial pulsations (Carare
et al., 2008; Dorr et al., 2012; Iliff et al., 2013b). Despite
little Aβ deposition, the structural and functional integrity of
venules and veins also deteriorate in AD, which may lead
to further impairments in amyloid clearance (Revesz et al.,
2003; Weller et al., 2009; Lai et al., 2015). The presence of
atherosclerosis is common in patients with AD, causing further
irregularities in vascularization including the thickening of the
perivascular space, which likely decreases vascular associated
Aβ clearance (Ross, 1993; Frink, 2002; Roher et al., 2003).
One of the major hallmarks of perivascular clearance is that
soluble Aβ deposits along capillaries and arteries as ISF drains
(Hawkes et al., 2013, 2014). Since para-venous drainage out
of the brain is proposed to occur in the glymphatic system,
it is surprising that Aβ deposits are not abundantly seen
along venules and veins (Revesz et al., 2003; Weller et al.,
2009; Iliff et al., 2012). There are a couple of explanations
for this observation. First, it is possible that the lack of
smooth muscle cells on veins provide less substrates for
Aβ to deposit on Weller et al. (2008). Secondly, peripheral
monocytes have been reported to enter the lumen of veins,
but not arteries, and clear soluble Aβ (Michaud et al.,
2013a).
Healthy lifestyle interventions play an important role in the
maintenance of the preceding Aβ clearance mechanisms. As
discussed above, consistent exercise, diet and sleep contribute
to proper structural and functional integrity of the vasculature,
maintaining regular blood vessel pulsations, which are the
driving force behind both the perivascular and glymphatic
clearance mechanisms (Carare et al., 2008; Iliff et al., 2013b).
Together these conclusions stress the importance of these lifestyle
interventions in the maintenance of vasculature health, and
subsequently in delaying the progression of AD.
Conclusion and Future Perspectives
In this review article, we have summarized three different
therapeutic approaches that rely on various combinations of
physiological Aβ clearance mechanisms. We have highlighted
some caveats to these approaches and attempted to highlight
mechanisms that might function in synergy to remove toxic
Aβ from the CNS as a disease-modifying therapy. The function
of the Aβ clearance mechanisms, efflux at the BBB, catabolism
within the CNS or drainage via either the perivascular drainage
pathway or glymphatics, must be considered when designing new
therapeutics and interpreting results from ongoing clinical trials,
including the potential exacerbation of clearance mechanisms
from small vessel arteriolar, capillary and venular disease. We
propose that clinical trial failure may not be the sole result of an
ineffective drug candidate or wrong patient population but may
represent a lack of endogenous clearance mechanisms needed to
support drug effects.
Although all cases of AD are characterized pathologically
in the same manner, the cause of disease and co-morbidities
that contribute to disease progression vary extensively between
patients. In light of this, multi-modal therapeutic approaches
may need to be considered, with an eye on personalized
medicine to account for the variability in presentation of
AD patients, including reliable quantification of subtypes of
small vessel disease as well as patterns of gray and white
matter atrophy, which is overlooked by many currently popular
automatic pipelines. Combination therapies are already in
practice for various diseases and thus may also be necessary
for AD. Furthermore, the treatment strategies may need to
vary depending on disease state or age of the individual at
presentation, with the goal of treating the disease or delaying the
onset.
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